Cosmetic Surgery Products

US demand to grow 6.5% annually through 2014
Demand for products used in cosmeticsurgery is forecast to increase 6.5 percentper year to $2.8 billion in 2014, when16.1 million cosmetic procedures areexpected to be performed. The economicrecession that began in December 2007impacted the cosmetic surgery industrymost profoundly in surgical procedures,which suffered large drops in 2008 and2009. Likewise, demand for equipmentused to perform these surgeries fell moresharply than did that for less expensive,non-invasive nonsurgical procedures.Busy lifestyles and pervasive unemploymentrates have led to rapid increases indemand for minimally invasive procedures(such as injections and laser-basedprocedures). Minimally or non-invasiveprocedures will continue to take marketshare from invasive surgeries, althoughhealthy growth will remain in some areas,such as implants, where there are nonotable alternatives.

Lasers, other light-based equipment to remain largest, fastest-growing
Equipment has traditionally held thelargest share of the cosmetic surgeryproduct market, and in 2009 accountedfor over one-third of demand. Purchasesof equipment were slowed by therecession and should see a strongrebound. Lasers and other light-basedsystems will continue to be the largestsector of equipment demand, and will seethe fastest growth going forward as newlaser-based treatments such as noninvasiveliposuction enter the market.

Injectables and implants fastest-growing products
Through 2014, injectables and implantswill continue to be the two fastestgrowingproduct segments. Growth indemand for injectables has boomed sincethe 1990s when BOTOX (Allergan) firstentered the market. Cosmetic injectionsbenefit from increasing societal acceptanceas well as high consumer awarenessof their ability to provide a quick, noninvasivereduction in wrinkles with norecovery time. With 2009 and 2010market approvals of competing botulinumtoxin-based injectables, BOTOX isseeing its first direct competition, whichis expected to have significant impact onthe market. Development of newergenerationsoft tissue fillers will alsocontinue, with this segment expected tosee the fastest gains among injectables.Implants will continue to benefit fromsilicone’s market re-entry in 2006, asbreast implants -- the most commonaesthetic surgical procedure -- remainfast-growing. Next-generation implantmaterials (so-called “gummy bear”implants) are forecast to enter the marketonce they receive FDA approval followingclinical testing. These higher-valueimplants will drive further value gains.

Please Note: Freedonia requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.